HALO - Halozyme Therapeutics Non-GAAP EPS of $0.47 misses by $0.02 revenue of $117.3M misses by $10.95M
Halozyme Therapeutics press release (NASDAQ:HALO): Q1 Non-GAAP EPS of $0.47 misses by $0.02. Revenue of $117.3M (+31.8% Y/Y) misses by $10.95M. Shares +0.68%.
For further details see:
Halozyme Therapeutics Non-GAAP EPS of $0.47 misses by $0.02, revenue of $117.3M misses by $10.95M